Stock · TORNTPHARM · Healthcare
TORNTPHARM share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for TORRENT PHARMACEUTICALS LIMITED, refreshed every end-of-day run. A systematic, data-only read on TORRENT PHARMACEUTICALS LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads TORNTPHARM as constructive with a Crack Score of 98/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 21 Jul 2026
Where TORNTPHARM stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
20/100Money flow
64/100Result pulse · Q4 FY26
0/100Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
at/near 52w high (<=3% off)
RSI 66.9 (strong)
above a rising MA frame
not over-extended (<5 ATR over 50DMA)
Red flags
above 200DMA (not a confirmed short-side trend)
weak filed result (score 0.0)
Relative valuation
P/E (TTM)
78.9P/E vs sector
+1.6%Sector percentile
81PEG
n/aScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for TORNTPHARM are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the TORNTPHARM chart, refreshed every end-of-day run.
The Crack Score, and how it is built98 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for TORNTPHARM, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on TORNTPHARM reads right now.
The editorial price read on TORNTPHARM is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on TORNTPHARM can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving TORNTPHARM.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why TORNTPHARM moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
TORRENT PHARMACEUTICALS LIMITED's most recent quarter, parsed straight from the official BSE filing. Every figure links back to its primary source.
Result Pulse
0 / 100Revenue
Rs 4,197 crNet profit
Rs 364 crEPS (quarter)
Rs 11.51| Growth | YoY | QoQ |
|---|---|---|
| Revenue | n/a | n/a |
| Net profit | n/a | n/a |
| Net margin | n/a | |
Figures are the Q4 FY26 result for TORRENT PHARMACEUTICALS LIMITED, parsed straight from the official BSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
TORRENT PHARMACEUTICALS LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
TORNTPHARM official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 4,197 cr | Rs 11.51 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 3,303 cr | Rs 18.77 | n/a | 58/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 3,302 cr | Rs 17.45 | n/a | n/a | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 3,178 cr | Rs 16.19 | n/a | n/a | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 2,959 cr | Rs 14.71 | n/a | n/a | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 2,809 cr | Rs 14.88 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 2,889 cr | Rs 13.37 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 2,859 cr | Rs 13.51 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 2,745 cr | Rs 13.27 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 2,732 cr | Rs 13.10 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 2,660 cr | Rs 11.39 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 2,591 cr | Rs 11.18 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 2,491 cr | Rs 8.48 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 2,491 cr | Rs 8.36 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 2,291 cr | Rs 9.22 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 2,347 cr | Rs 20.90 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 2,131 cr | Rs -6.98 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 2,108 cr | Rs 14.75 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 2,137 cr | Rs 18.63 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 2,134 cr | Rs 19.53 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 1,937 cr | Rs 19.16 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 1,995 cr | Rs 17.52 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 2,017 cr | Rs 18.32 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 2,056 cr | Rs 18.98 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 1,946 cr | Rs 18.56 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 1,966 cr | Rs 14.77 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 2,005 cr | Rs 14.48 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 2,022 cr | Rs 12.74 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Consolidated, audited | Rs 1,856 cr | Rs -8.95 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Consolidated, audited | Rs 2,051 cr | Rs 14.50 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Consolidated, audited | Rs 1,894 cr | Rs 10.57 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Consolidated, audited | Rs 1,872 cr | Rs 9.66 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
TORRENT PHARMACEUTICALS LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
13,980 crNet profit (TTM)
2,138 crEBIT (TTM)
3,257 crProfit before tax (TTM)
2,872 crNet margin (TTM)
15.3%Finance costs (TTM)
385 crBalance sheet, as filed 2026-03-31
Total assets
44,312 crShareholder equity
17,585 crTotal borrowings
14,798 crCash and equivalents
1,117 crInventory
3,138 crTrade receivables
3,031 crThe cash engine, latest filed year
Operating cash flow
3,023 crCapex
677 crFree cash flow
2,346 crInvesting flow
12,713 crFinancing flow
10,151 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 13,980 cr | 2,138 cr | 17,585 cr | 14,798 cr | 3,023 cr |
| FY25 | 11,516 cr | 1,911 cr | 7,591 cr | 3,026 cr | 2,585 cr |
| FY24 | 10,728 cr | 1,656 cr | 6,856 cr | 3,938 cr | 3,266 cr |
| FY23 | 9,620 cr | 1,245 cr | 6,198 cr | 5,297 cr | 2,368 cr |
| FY22 | 8,508 cr | 777 cr | 5,953 cr | 4,018 cr | 1,803 cr |
| FY21 | 8,005 cr | 1,252 cr | 5,838 cr | 3,645 cr | n/a |
Every figure is parsed from TORRENT PHARMACEUTICALS LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record24 earnings calls
Every TORNTPHARM earnings call BazaarBaazi has indexed, latest 28 Feb 2026. Read management in its own words, straight from the filed transcript.
TORRENT PHARMACEUTICALS LIMITED earnings calls on record
24 calls since 28 Feb 2018
Show 16 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed1 disclosure
Every recent official filing from TORRENT PHARMACEUTICALS LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
TORRENT PHARMACEUTICALS LIMITED's most recent official filing is a Earnings dated 31 Mar 2026.
Event Heat
61 / 100Event Heat is a dated net read of TORRENT PHARMACEUTICALS LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the TORNTPHARM chart. Not a substitute for a registered research note.
| Ticker | TORNTPHARM |
|---|---|
| Full name | TORRENT PHARMACEUTICALS LIMITED |
| Sector | Healthcare |
| Index class | LARGE CAP |
| ISIN | INE685A01028 |
| Market-cap band | ~1.6 lakh cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | TORNTPHARM |
Reference chart4 Sep 2025
The daily frame the desk reads on TORNTPHARM.
FAQ11 reader questions · AEO-eligible
The line on TORNTPHARM, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the TORNTPHARM share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on TORNTPHARM. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for TORNTPHARM?
The BazaarBaazi Crack Score for TORNTPHARM is 98 out of 100 as of 21 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on TORNTPHARM?
Strike-level option inventory for TORNTPHARM is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is TORNTPHARM in and which peers does BazaarBaazi track?
TORNTPHARM sits in Healthcare (large cap), indicative market cap ~1.6 lakh cr (indicative), ISIN INE685A01028. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on TORRENT PHARMACEUTICALS LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the TORNTPHARM view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on TORNTPHARM is bullish, published in Systematic Read on 21 Jul 2026.
Is TORNTPHARM a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, TORRENT PHARMACEUTICALS LIMITED sits in the Scanned tier with a setup score of 67/100 (technical 100, fundamental 20). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read TORRENT PHARMACEUTICALS LIMITED's earnings call transcripts?
BazaarBaazi indexes 24 TORNTPHARM earnings calls going back to 2018-02-28, latest 2026-02-28. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was TORRENT PHARMACEUTICALS LIMITED's Q4 FY26 net profit?
TORRENT PHARMACEUTICALS LIMITED reported a net profit of Rs 364 cr for Q4 FY26 (the quarter ended 31 March 2026). The figure is from the company's official NSE filing.
What was TORRENT PHARMACEUTICALS LIMITED's Q4 FY26 revenue?
TORRENT PHARMACEUTICALS LIMITED reported revenue of Rs 4,197 cr for Q4 FY26. The figure is from the company's official NSE filing.
How does BazaarBaazi rate TORRENT PHARMACEUTICALS LIMITED's Q4 FY26 result?
BazaarBaazi gives TORRENT PHARMACEUTICALS LIMITED's Q4 FY26 result a Result Pulse of 0 out of 100, with a verdict of Insufficient data. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Torrent Pharmaceuticals Ltd announced recently?
The most recent official filing on record for Torrent Pharmaceuticals Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside TORNTPHARM, each a living view refreshed every end-of-day run.